Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Clinical trial NCT01221103 · UNKNOWN

Trial details

NCT number: NCT01221103
Sponsor: Southern Europe New Drug Organization
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphoma, Mantle-Cell

Start date: 2010-04-01
Primary completion: 2012-04-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.